Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020575 | 0.86 | CHRNA7 (0.75) | CHRNA7CYP2D6 | |
| SCHEMBL3032110 | 0.84 | CHRNA7 (0.74) | CHRNA7CYP2D6 | |
| SCHEMBL3029311 | 0.83 | CHRNA7 (0.78) | CHRNA7CYP2D6 | |
| SCHEMBL1459705 | 0.81 | CHRNA7 (1.00) | CHRNA7CYP2D6 | |
| SCHEMBL3030941 | 0.81 | CHRNA7 (0.73) | CHRNA7CYP2D6 | |
| SCHEMBL3025893 | 0.80 | CHRNA7 (0.83) | CHRNA7CYP2D6 | |
| SCHEMBL3032537 | 0.80 | CHRNA7 (0.66) | CHRNA7CYP2D6 | |
| SCHEMBL3015623 | 0.79 | CHRNA7 (1.00) | CHRNA7CYP2D6 | |
| SCHEMBL3029112 | 0.79 | CHRNA7 (0.73) | CHRNA7CYP2D6 | |
| SCHEMBL3025950 | 0.79 | CHRNA7 (0.81) | CHRNA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | claimed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | claimed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | claimed |
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | CHRNA7 4801/4885CYP2D6 253/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | CHRNA7 4801/4885CYP2D6 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.